Therapeutic potential of new hydrogen sulfide-releasing hybrids

Expert Review of Clinical Pharmacology

Volumn 4, Issue 1, 2011, Pages 109-121

  Sparatore, Anna ^a   Santus, Giancarlo ^b   Giustarini, Daniela ^c   Rossi, Ranieri ^c   Del Soldato, Piero ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CTG Pharma   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

biomarker; dithiolethione; gaseous transmitter; glutathione; H 2S donating hybrids; hydrogen sulfide

Indexed keywords

2 [(2,6 DICHLOROPHENYL)AMINO]BENZENEACETIC ACID 4 (3H 1,2 DITHIOL 3 THIONE 5 YL)PHENYL ESTER; 5 (4 HYDROXYPHENYL) 1,2 DITHIOL 3 THIONE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ANETHOLE DITHIOLETHIONE; ANTIINFLAMMATORY AGENT; BUTHIONINE SULFOXIMINE; CHOLERETIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC DERIVATIVE; GLIBENCLAMIDE; HYDROGEN SULFIDE; INDOMETACIN; LATANOPROST; LEVODOPA; MESALAZINE; NAPROXEN; NAPROXEN DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE ASPIRIN; NITRIC OXIDE NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; S ASPIRIN; S DICLOFENAC; S LATANOPROST; S SILDENAFIL; SILDENAFIL; THIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; BONE METASTASIS; CROHN DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENCEPHALITIS; GASTROINTESTINAL TOXICITY; GLAUCOMA; HEART PROTECTION; HUMAN; INFLAMMATION; LIVER TOXICITY; LUNG INJURY; METABOLITE; NEPHROTOXICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; STOMACH EROSION; STOMACH HEMORRHAGE; ULCERATIVE COLITIS; UROLOGY; VISCERAL PAIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DICLOFENAC; HUMANS; HYDROGEN SULFIDE; INFLAMMATION; LEVODOPA; PRODRUGS; PROSTAGLANDINS F, SYNTHETIC;

EID: 78650435016     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.122     Document Type: Review

References (68)

1. 2S gas biology. Antioxid. Redox Signal. 13(2), 157-192 (2010).
2. Wang R. Toxic gas, lifesaver. Sci. Am. 302(3), 66-71 (2010).
3. Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide and inflammation - a tale of three gases! Pharmacol. Ther. 123(3), 386-400 (2009).
4. 2S. Acta Histochem. 111(3), 244-256 (2009).
5. Turnbull CM, Rossi, AG, Megson IL. Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opin. Ther. Targets 10(6), 911-922 (2006).
6. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. NY Acad. Sci. 962, 360-371 (2002).
7. Li L, Moore PK. Putative biological roles of hydrogen sulphide in health and disease: a breath of not so fresh air? Trends Pharmacol. Sci. 29(2), 84-90 (2008).
8. Cooper CE, Brown GC. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulphide: chemical mechanism and physiological significance. J. Bioenerg. Biomembr. 40(5), 533-539 (2008).
9. Goubern M, Andriamihaja M, Nubel T, Blachier F, Bouillaud F. Sulfide, the first inorganic substrate for human cells. FASEB J. 21(8), 1699-1706 (2007).
10. Abu-Mohamed G, Johnson JA, EL-Remessy AB et al. Role of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin. J. Pharmacol. Exp. Ther. 308(1), 289-299 (2004).
11. Grosser N, Schroeder H. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate. Biochem. Biophys. Res. Commun. 274(1), 255-258 (2000).
12. Lee DH, Pfeifer GP. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis 22(1), 63-67 (2007).
13. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med. 42(5), 706-719 (2007).
14. 2S-releasing aspirin. Free Radic. Biol. Med. 48(9), 1263-1272 (2010).
15. Giustarini D, Perrino E, Tazzari V, Rossi R. HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(3-4), 340-346 (2009).
16. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem. 390(3), 191-214 (2009).
17. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin. Thromb. Hemost. 26(3), 219-225 (2000).
18. Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 39(42), 13005-13011 (2000).
19. 2S biogenesis by human cystathionine γ-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J. Biol. Chem. 284(17), 11601-11612 (2009).
20. Szabò C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6(11), 917-935 (2007).
21. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid. Redox Signal. 12(1), 1-13 (2010).
22. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther. 7(11), 3470-3479 (2008).
23. Ansher SS, Dolan P, Buending E. Biochemical effects of dithiolthiones. Food Chem. Toxicol. 24(5), 405-415 (1986).
24. Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 41(1), 69-77 (2008).
25. Viegas-Junior C, Danuello A, Da Silva Bolzani V, Barreiro EJ, Manssour Fraga CA. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr. Med. Chem. 14, 1829-1852 (2007). 26 Sidhapuriwala J, Li L, Sparatore A, Bhatia M, Moore PK. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. Eur. J. Pharmacol. 569(1-2), 149-154 (2007).
26. Wallace JL, Caliendo G, Santagata V, Cirino G, Fiorucci S. Gastrointestinal safety and antinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132(1), 261-271 (2007).
27. 2S-releasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock 29(1), 84-88 (2008) 29 Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soladato P, Berti F. The hydrogen sulfide-releasing derivative of diclofenac protects against ischaemia- reperfusion injury in the isolated rabbit heart. Br. J. Pharmacol. 153(1), 100-109 (2008).
28. Conforti A, Donini M, Brocco G, Del Soldato P, Benoni P, Cuzzolin L. Acute antiinflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac. Agents Actions 40(3-4), 176-180 (1993).
29. Cuzzolin L, Conforti A, Donini M, Adami A, Del Soldato P, Benoni G. Effects on intestinal microflora, gastrointestinal tolerability and antiinflammatory efficacy of diclofenac and nitrofenac in adjuvant arthritic rats. Pharmacol. Res. 29(1), 89-97 (1994).
30. Isenberg JS, Jia Y, Field L, et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br. J. Pharmacol. 151(1), 63-72 (2007).
31. Reuter S, Gupta SC, Chaturvedi MM, Bharat BA. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. DOI: 10.1016/j. freeradbiomed.2010.09.006 (2010) (Epub ahead of print). 34 Papapetropoulos A, Pyriochou A, Altaany Z et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 106(51), 21972-21977 (2009).
32. Baskar R, Sparatore A, Del Soldato P, Moore PK. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 594(1-3), 1-8 (2008).
33. Idris AI, Frantzias J, Sparatore A, Del Soldato P, Ralston SH. Identification of hydrogen sulfide releasing compounds as novel antiresorptive and antitumour agents. Presented at: 10th International Conference on Cancer-Induced Bone Disease. Sheffield, UK, 22-25 September 2010.
34. Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol. Sci. 28(10), 501-505 (2007).
35. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol. 159(6), 1236-1246 (2010).
36. Rosenthal D, Taylor TI. Mechanism and kinetics of the thioacetamide hydrolysis reaction. JACS 79, 2684-2690 (1957).
37. Taurog A. Hormone synthesis: tyroid iodine methabolism. In: Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text (8th Edition). Braverman LE, Utiger RD (Eds). Lippincott Williams & Wilkins, PA, USA 61-84 (2000).
38. Taurog A. The mechanism of action of the thioureylene antithyroid drugs. Endocrinology 98, 1031-1046 (1976).
39. Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, Hanzlik RP. Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. Chem. Res. Toxicol. 21(7), 1432-1442 (2008).
40. Warnet JM, Christen MO, Thevenin M, Briard D, Jaqueson A, Claude JR. Protective effect of anethole dithiolthione against acetaminophen hepathotoxicity in mice. Pharmacol. Toxicol. 65(1), 63-64 (1989).
41. Christen MO. Anethole dithiolethione: biochemical considerations. Meth. Enzymol. 252, 316-323 (1995).
42. Fiorucci S, Orlandi S, Mencarelli A et al. Enhanced activity of a hydrogen sulphide releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br. J. Pharmacol. 150, 996-1002 (2007).
43. Distrutti E, Sediari L, Mencarelli A et al. 5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenylester (ATB-429), a hydrogen sulfidereleasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J. Pharmacol. Exp. Ther. 319(1), 259-271 (2006).
44. Del Soldato P, Sorrentino R, Pinto, A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20, 319-323 (1999).
45. Fiorucci S, Antonelli E, Santucci LA. Gastrointestinal safety of nitric oxidederived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 116, 1089-1106 (1999).
46. Fiorucci S, Santucci L, Gresele P, Maffei-Facino R, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124, 600-607 (2003).
47. 2S-releasing aspirin. Free Radic. Biol. Med. 46(5), 586-592 (2008).
48. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu. Rev. Med. 60, 39-54 (2009).
49. Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr. Clin. Pharmacol. 5(1), 30-36 (2010).
50. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst. Rev. (4), CD006612 (2009).
51. Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. N. Engl. J. Med. 354 (15), 1629-1632 (2006).
52. Urquhart BL, Freeman DJ, Spence JD, House AA. Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis. J. Clin. Pharmacol. 47(8), 991-997 (2007).
53. Giral P, Jacob N, Dourmap C et al. Elevated γ-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(3), 587-593 (2008).
54. Rossoni G, Manfredi B, Tazzari V et al. Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats. Eur. J. Pharmacol. 648(1-3), 139-145 (2010).
55. Shukla N, Rossoni G, Hotston M et al. Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats. BJU Int. 103(11), 1522-1529 (2009).
56. Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr. Vasc. Pharmacol. 4, 89-93 (2006).
57. 2S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G. Br. J. Pharmacol. 155(7), 984-994 (2008).
58. Kimura Y, Kimura H. Hydrogen sulphide protects neurons from oxidative stress. FASEB J. 18(10), 1165-1167 (2004).
59. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J. Neurovirol. 8(6), 529-538 (2002).
60. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150(8), 963-976 (2007).
61. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 58(1), 103-113 (2010).
62. Lee M, Tazzari V, Giustarini D et al. Effects of hydrogen sulfide-releasing l-DOPA derivatives on glial activation: potential for treating Parkinson disease. J. Biol. Chem. 285(23), 17318-17328 (2010).
63. Benavides GA, Squadrito GL, Mills RW. Hydrogen sulfide mediates the vasoactivity of garlic. Proc. Natl Acad. Sci. USA 104(46), 17977-17982 (2007).
64. Leske MC, Heijl A, Hyman L, Bengtsson B, Yang Z; EMGT Group. Predictors of long term progression in the early manifest glaucoma trial. Ophtalmology 114(11), 1965-1972 (2007)
65. Higginbotham EJ, Gordon MO, Beiser JA et al; Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch. Ophthalmol. 122(6), 813-820 (2004).
66. McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care 14(1 Suppl.), S20-S27 (2008). (Pubitemid 351341925)
67. Osborne NN, Ji D, Abdul Majid AS, Fawcett RJ, Sparatore A, Del Soldato P. ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture. Invest. Ophthalmol. Vis. Sci. 51, 284-294 (2010).
68. Perrino E, Uliva C, Lanzi C, Del Soldato P, Masini E, Sparatore A. New prostaglandin derivative for glaucoma treatment. Bioorg. Med. Chem. Lett. 19(6), 1639-1642 (2009).